Passage Bio, Inc. Price & Performance (PASG)

GRO Biosciences has announced layoffs as it seeks strategic alternatives to advance its lead program, ProGly-Uricase, targeting severe gout. The company, which raised $60.3 million in a Series B round last year, is restructuring to overcome challenges in its clinical trial pipeline and maintain its operational focus.12

Passage Bio’s stock has plunged to a 52-week low of $0.38, reflecting investor concerns over its financial health and rapid cash burn. The company, which recently transitioned to Nasdaq’s Capital Market, is implementing operational changes, including workforce reductions, to extend its financial runway into 2027.34

iECURE has shared initial data from its gene editing trial targeting neonatal OTC deficiency. The results indicate potential for addressing this rare metabolic disorder, showcasing advancements in gene therapy. This marks a significant step forward in the clinical use of gene editing for severe genetic conditions.5